Chào mừng trở lại
Tham gia Cointime
Đăng nhập với email
Đăng nhập với
Đăng ký
ITeos Therapeutics
About
ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.
- 101 - 250
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- €9M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2011
- Number Of Employee
- 101 - 250
- Operating Status
- Active
ITeos Therapeutics is a private biotechnology company targeting the metabolism of the tumor microenvironment to develop small molecule immunomodulators for cancer treatments. iTeos is building its activities upon the unparalleled expertise of the Ludwig Cancer Research (LICR) – a world-class Research Institute in the fields of tumor immunology, therapeutic cancer vaccines, cancer biology, and translational medicine in cancer.iTeos endeavors to develop small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints (e.g. anti-CTLA4, anti-PD1, and anti-PDL1 antibodies).
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 20, 2018 | Series B | $75M | 1 | — | — | Detail |
| May 3, 2012 | Series A | €9M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series B |
